SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Cardiovascular disease
Ionis’ Tryngolza Hits ‘Best-Case Scenario’ in Late-Stage Triglyceride Study
Aside from lowering triglyceride levels, Ionis’ olezarsen reduced acute pancreatitis events, an outcome that BMO Capital Markets said could help the asset deliver a “significant first-in-class commercial launch.”
September 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Modern collage with human heart and hands stock illustration
Cardiovascular disease
Cytokinetics Soars on Aficamten’s ‘Best-in-Class’ Performance in Phase III Cardio Study
Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.
September 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
CDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More
Health Secretary Robert F. Kennedy Jr. will appear before the Senate Finance Committee Thursday, ahead of a vaccine advisory committee meeting later in September. Meanwhile, deal-making appetite appears healthy, and the weight loss space continues generating clinical data and other news.
September 3, 2025
 · 
1 min read
 · 
Jef Akst
Illustration showing hands with graph and diagram in trendy vintage style as a concept of analytics
Job Trends
Data Scientist Fourth Fastest-Growing U.S. Job, Says BLS
Data scientist employment is expected to grow 33.5% from 2024 to 2034 due in part to a growing demand for data analysis, according to new U.S. Bureau of Labor Statistics findings. Biopharma hotspots were among the top 10 states for employment and pay for this role in 2024.
September 3, 2025
 · 
2 min read
 · 
Angela Gabriel
Three-dimensional composite image, which can be used in any design
Opinion
Gene Therapy Should Not Be a Luxury
It can cure deadly diseases, save long-term healthcare costs and transform lives. But the U.S. insurance system still isn’t ready to pay for it.
September 3, 2025
 · 
7 min read
 · 
Dennis Sponer
Changing or transforming, turning around, challenging the odds and conquering adversity, a businessman pole vaulting from the down arrow to the up arrow of growth
IPO
SPACs Line Up To Clear Biotech’s IPO Backlog
Blank check deals dwindled after a crazy 2021. Now, biotechs are starting to turn to special purpose acquisition companies again as an easy route to the public markets.
September 3, 2025
 · 
6 min read
 · 
Annalee Armstrong
A hand about to burst a money bubble with a pin. Metaphor for an economic or financial bubble crisis.
IPO
After 2021 SPAC Bubble, How Did These 6 Biotechs Fare?
Some of the biggest SPACs from the industry’s pandemic-fueled heyday are no longer on the market.
September 3, 2025
 · 
10 min read
 · 
Tristan Manalac
A red paper airplane with a fighter jet shadow changes course from a group of other paper airplanes, a concept of different business and social behaviors. Vector illustration.
IPO
After Short Stint as a Private Company, BBOT Leaves SPAC Process Ready To Execute
After spinning out of BridgeBio in May 2024, BBOT had an eye on another round of fundraising in 2025. A SPAC quickly emerged as the best option.
September 3, 2025
 · 
3 min read
 · 
Annalee Armstrong
FDA
Offit Out at FDA Vaccine Advisory Committee After HHS Rebuff
Paul Offit, longtime member of the FDA’s vaccine advisory committee and an outspoken critic of Health Secretary Robert F. Kennedy Jr., was recently informed by the Department of Health and Human Services that his services are no longer required.
September 2, 2025
 · 
3 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS